| Bioactivity | MB076 is a novel heterocyclic triazole with improved plasma stability. MB076 inhibits seven different Class C Acinetobacter-derived cephalosporinases (ADCs) β-lactamase variants with Ki values ＜ 1 μM. MB076 acts synergistically in combination with multiple cephalosporins to restore pBCSK(−) susceptibility[1]. |
| Target | Ki Target: ADC-7, ADC-30, ADC-162, ADC-33, ADC-219, ADC-212Ki: 0.21±0.016 μM (ADC-7), 0.058±0.005μM (ADC-30), 0.79±0.039μM (ADC-162), 0.10±0.004μM (ADC-33), 0.11±0.019 (ADC-219), 0.61±0.038μM (ADC-212) |
| Invitro | MB076 (compound B) (0.5-5 μM, 48 h) 在人血浆中的稳定性有所提高[1]。MB076 (10 μg/mL, 48 h) 与 Ceftazidime (CAZ HY-B0593)、 Cefotaxime (CTXHY-A0088A) 联合可协同恢复 pBCSK(−) 药敏[1]。 0 --> MB076 相关抗体: Cell Viability Assay[1] Cell Line: |
| Name | MB076 |
| CAS | 2832966-95-5 |
| Formula | C9H12BN7O5S2 |
| Molar Mass | 373.18 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Rachel A. Powers, et al. Synthesis of a Novel Boronic Acid Transition State Inhibitor, MB076: A Heterocyclic Triazole Effectively Inhibits Acinetobacter-Derived Cephalosporinase Variants with an Expanded-Substrate Spectrum. J Med Chem. 2023 Jul 13; 66(13): 8510–8525. |